Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 402 Shares

Posted by George Bondi on Jun 11th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) insider Dennis Cho sold 402 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $69.84, for a total value of $28,075.68. Following the completion of the sale, the insider owned 119,692 shares of the company’s stock, valued at approximately $8,359,289.28. This trade represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $67.77 on Thursday. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $80.50. The firm’s fifty day simple moving average is $58.61 and its 200 day simple moving average is $46.93. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $4.22 billion, a PE ratio of -50.95 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm had revenue of $110.72 million during the quarter, compared to analyst estimates of $107.64 million. During the same quarter in the previous year, the business posted ($0.66) earnings per share. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Twist Bioscience Corporation will post -1.99 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on TWST. Barclays upped their target price on Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Guggenheim raised their price target on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Leerink Partners set a $80.00 price objective on shares of Twist Bioscience in a report on Friday, May 22nd. Finally, Robert W. Baird raised their target price on Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $58.00.

Get Our Latest Stock Report on TWST

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TWST. Quarry LP acquired a new position in shares of Twist Bioscience during the 3rd quarter worth approximately $28,000. Smartleaf Asset Management LLC boosted its stake in Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares during the period. Western Wealth Management LLC bought a new stake in Twist Bioscience in the 1st quarter valued at $31,000. Strs Ohio bought a new stake in Twist Bioscience in the 1st quarter valued at $33,000. Finally, Strategic Advocates LLC lifted its position in shares of Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after acquiring an additional 906 shares during the period.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.